LIVE QUOTE
STERIS plc STE
Healthcare · Medical - Devices · NYSE
$212.88
Market Cap$22.0B
P/E Ratio28.0
Dividend Yield0.90%
Beta0.92
Employees18,000

Investment Thesis

STERIS plc presents a compelling BUY opportunity at current prices around $212.88, driven by its integral role in infection prevention and procedural support in the healthcare sector. The market appears to undervalue the company's robust service offerings, diversified revenue streams, and strong position in both the Healthcare and Life Sciences segments, which are essential in a post-pandemic world. Given the company’s strategic focus on innovation and operational excellence, it is likely to outperform expectations in a growing healthcare market, suggesting that the current stock price does not fully reflect STERIS's potential.

Competitive Moat

characterized by high switching costs and intangible assets, particularly in the form of regulatory compliance and brand reputation. Hospitals and healthcare providers face substantial costs and operational risks when changing sterilization vendors or switching equipment suppliers, effectively locking in long-term relationships with STERIS. This advantage is durable over the next 5-10 years, especially as stringent regulatory standards for infection control and sterilization continue to evolve. Key competitive threats include emerging technologies from smaller startups that may offer disruptive alternatives and larger players that could leverage economies of scale to undercut pricing.

Growth Engine

Future revenue growth for STERIS will largely stem from organic expansion in healthcare services, particularly in its Healthcare and Life Sciences segments, which are projected to grow at an accelerated pace due to increased global health expenditures. The total addressable market for infection prevention services and medical devices is on an upward trajectory, bolstered by rising awareness of hygiene and safety protocols post-COVID-19. Additionally, STERIS is likely to benefit from geographic expansion into emerging markets and the introduction of new innovative products, particularly in sterilization technologies. The company is currently gaining market share, supported by its extensive service network and strong client relationships.

This analysis is AI-generated using publicly available market data and is for informational purposes only. It does not constitute investment advice. Always conduct your own research before making investment decisions.
Morningstar Investor
Analyst ratings, fair value, moat
Research STE
Robinhood
$0 commission trades
Trade STE
Webull
Extended-hours, options, charts
Trade STE
TradingView
Advanced charts & screeners
Chart STE
We may earn a commission if you open an account through our links, at no extra cost to you.
Loading chart...

Frequently Asked Questions

As of 2026-06-15, STERIS plc (STE) has a P/E ratio that is not available, which may indicate the company is not currently profitable or is in a growth phase. Additionally, without a specified market cap, it's challenging to assess its valuation relative to its sector, which could influence investment decisions.
STERIS plc does not currently pay a dividend, as there is no dividend yield available.
STERIS plc operates in the Healthcare sector, specifically within the Medical - Devices industry.
The market cap for STERIS plc is not available, but given its price of $212.88 as of 2026-06-15, it is important to note that it may be classified as a large-cap company if it exceeds $10 billion.
Competitors of STERIS plc in the medical devices industry include companies such as Medtronic and Johnson & Johnson, which also offer a range of healthcare products and services.
FAQ generated 2026-06-15

Related Reading

Related Stocks

← View in Stock Screener
Disclaimer: Stock data sourced from Financial Modeling Prep, updated daily. Prices may be delayed. Interactive charts powered by TradingView. This page is for informational and educational purposes only and does not constitute investment advice. We are not licensed financial advisors. Past performance is not indicative of future results. All investments carry risk, including the possible loss of principal. Please consult a qualified professional before making investment decisions.

Privacy Policy · Terms